This phase I trial is trying to determine the safety and effectiveness of an immunotherapy drug, given alone and as a combination therapy for mesothelin-expressing advanced cancers.
This trial is treating patients with breast or pancreatic cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
This trial is open for recruitment for patients with Breast Cancer (Triple Negative Breast Cancer) and Pancreatic adenocarcinoma. Other cohorts, which are now closed include Non-Small Cell Lung Cancer, Cholangiocarcinoma, Gastric Adenocarcinoma, Thymic carcinoma. Eligible patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine will be administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). Treatment will continue until disease progression.
Not Recruiting Hospitals Read More